A 24-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase II Study With an Optional 28-week Open-label Extension to Evaluate the Efficacy on Body Weight of Dapagliflozin 10 mg Once Daily in Combination With Exenatide 2 mg Once Weekly in Obese Non-diabetic Subjects.
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms Dapalost
- 07 Jun 2017 Biomarkers information updated
- 16 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes